A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
This study is recruiting at 12 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colitis, Ulcerative
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2/3
- Ages
- 2 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- September 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Loma Linda University Health System · Loma Linda, CA
- Cedars-Sinai Medical Center · Los Angeles, CA
- University of California Davis Health · Sacramento, CA
Massachusetts · 2
- Boston Children's Hospital · Boston, MA
- University of Massachusetts Chan Medical School · Worcester, MA
Minnesota · 1
- Mayo Clinic in Rochester, Minnesota · Rochester, MN
Missouri · 1
- Washington University · St Louis, MO
New York · 1
- Columbia University Medical Center · New York, NY
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Texas · 1
- Texas Children's Hospital · Houston, TX
Washington · 2
- Seattle Children's Hospital · Seattle, WA
- MultiCare Health System · Tacoma, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.